Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
|
10.8B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
984.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
243.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
306B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.2B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Shandong Xinhua Pharmaceutical Co Ltd
Glance View
In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Shandong Xinhua Pharmaceutical Co Ltd is 5.4%, which is below its 3-year median of 6.3%.
Over the last 3 years, Shandong Xinhua Pharmaceutical Co Ltd’s Operating Margin has decreased from 6.1% to 5.4%. During this period, it reached a low of 5.4% on Sep 30, 2025 and a high of 6.9% on Sep 30, 2023.